Tandem Diabetes

Q2 FY2026 EarningsQ2 FY2026 results were mixed relative to consensus: revenue of $254.6M was in-line with the $255.1M expected, while gross margin significantly beat at 57.0% vs. 55.2% expected. GAAP EPS of -$0.31 was slightly ahead of the -$0.32 consensus. Despite the margin strength, worldwide pump shipments of 33,000 drove only 6% YoY sales growth, and the company merely reaffirmed its FY2026 revenue guidance of $1.065B-$1.085B, suggesting a cautious outlook for the second half.